0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Research Letter | 
Nynne Nyboe Andersen, MD; Björn Pasternak, MD, PhD; Mikael Andersson, MSc; et al.
JAMA Intern Med. 2015;175(12):1990-1992. doi:10.1001/jamainternmed.2015.5396.

Research Letter |  FREE
Michael D. Botta, PhD; Robert J. Blendon, ScD; John M. Benson, MA
JAMA Intern Med. 2014;174(1):141-143. doi:10.1001/jamainternmed.2013.11332.
Includes: Supplemental Content

Perspective | 
Anna Petroni
JAMA Intern Med. 2013;173(13):1173. doi:10.1001/jamainternmed.2013.6509.

Original Investigation |  FREE
Richard A. Hughes, FRCP; Judith Charlton, MSc; Radoslav Latinovic, BSc; et al.
Arch Intern Med. 2006;166(12):1301-1304. doi:10.1001/archinte.166.12.1301.

Review Article |  FREE
Steven L. Galetta, MD; Clyde Markowitz, MD; Andrew G. Lee, MD
Arch Intern Med. 2002;162(19):2161-2169. doi:10.1001/archinte.162.19.2161.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Neurology
Original Investigation  | 
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders A Systematic Review and Meta-analysis
Valentina Damato, MD; Amelia Evoli, MD; Raffaele Iorio, MD, PhD
JAMA Neurology
Editorial  | 
Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis
Edward R. Hammond, MD, PhD, MPH
JAMA Neurology
Original Investigation  | 
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study
Ludwig Kappos, MD; David K. B. Li, MD; Olaf Stüve, MD; et al.
JAMA Neurology
Editorial  | 
Cortical Volume Loss and Neurologic Dysfunction in Multiple Sclerosis
Michael K. Racke, MD; Jaime Imitola, MD